Hamps Bio Limited
Incorporated in 2007, Hamps Bio Ltd is in the business of Pharmaceutical Formulation and Freeze-Drying Ingredient Manufacturing and Distribution[1]
- Market Cap ₹ 21.8 Cr.
- Current Price ₹ 25.0
- High / Low ₹ 35.0 / 13.4
- Stock P/E
- Book Value ₹ 9.30
- Dividend Yield 0.00 %
- ROCE -33.7 %
- ROE -87.5 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.69 times its book value
- Company has low interest coverage ratio.
- Earnings include an other income of Rs.3.32 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 66.69 | 84.75 | |
| 58.99 | 84.41 | |
| Operating Profit | 7.70 | 0.34 |
| OPM % | 11.55% | 0.40% |
| 1.51 | 3.32 | |
| Interest | 1.40 | 2.49 |
| Depreciation | 3.77 | 8.17 |
| Profit before tax | 4.04 | -7.00 |
| Tax % | 26.49% | 5.57% |
| 2.98 | -7.39 | |
| EPS in Rs | 3.43 | -8.48 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -348% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -87% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 4.36 | 8.71 |
| Reserves | 4.44 | -0.61 |
| 2.97 | 6.88 | |
| 1.02 | 0.94 | |
| Total Liabilities | 12.79 | 15.92 |
| 2.59 | 9.10 | |
| CWIP | 3.28 | 1.08 |
| Investments | 0.00 | 0.07 |
| 6.92 | 5.67 | |
| Total Assets | 12.79 | 15.92 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Net Cash Flow | ||
| Free Cash Flow | ||
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 6.51 | 6.85 |
| Inventory Days | 43.46 | 29.75 |
| Days Payable | 10.96 | 3.92 |
| Cash Conversion Cycle | 39.01 | 32.68 |
| Working Capital Days | 12.42 | 6.50 |
| ROCE % | -33.72% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Number of Manufacturing Units Number ・Standalone data |
|
|
| Number of SKUs - FMCG Division (Brand: FRYZEY) Number ・Standalone data |
||
| Number of SKUs - Pharma Division Number ・Standalone data |
||
| Solar Power Plant Capacity (Ankleshwar Unit) kVA ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
29 May - M/s Naviwala & Associates appointed internal auditor for FY 2026-27, effective May 29, 2026.
- Results - Financial Results For The Year Ended 31-03-2026 29 May
-
Board Meeting Outcome for Board Meeting Outcome For Approval Of Standalone And Consolidated Audited Financial Results For The Half Year And Year To Date Ended March 31, 2026, Along With Auditor''s Report Thereon Is Attached Herewith.
29 May - Board approved audited standalone and consolidated results for FY2026; appointed Naviwala & Associates as internal auditor.
-
Board Meeting Intimation for Board Meeting Intimation For Approval Of The Audited Standalone And Consolidated Financial Results Of The Company For The Half Year And Year To Date Ended March 31, 2026
25 May - Board meeting on May 29, 2026 to approve audited FY26 results and appoint internal auditor.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended on March 31, 2026.
Business Overview:[1]
HBL is in the business of ethical marketing and distribution of pharmaceutical formulations across wide range of dosage including tablets, syrups, capsules, injectables, oil, gel and powder used as medicine & nutrition supplements as well as the manufacturing of freeze dried and frozen products such as fruits, vegetables, herbs and flowers.